Vera Therapeutics/$VERA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Vera Therapeutics

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Ticker

$VERA
Sector
Health
Primary listing
NASDAQ

Employees

192
Headquarters
Brisbane, United States
Website
veratx.com

VERA Metrics

BasicAdvanced
$1.6B
-
-$4.00
1.22
-

What the Analysts think about VERA

Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.

Bulls say / Bears say

The ORIGIN Phase 3 trial achieved its main goal, with atacicept reducing proteinuria by 46% from baseline and by 42% versus placebo at week 36 (p<0.0001), providing statistically significant and clinically meaningful results in IgAN (GlobeNewswire).
Late-breaking ORIGIN Phase 3 data presented at ASN Kidney Week 2025 and published in NEJM showed atacicept lowered Gd-IgA1 by 68%, resolved hematuria in 81% of patients, and maintained a favorable safety profile with fewer serious adverse events than placebo (0.5% vs 5%) through 96 weeks (GlobeNewswire).
As of September 30, 2025, Vera had $497.4 million in cash, cash equivalents, and marketable securities, plus available debt financing, which it believes will fund operations through the potential approval and U.S. launch of atacicept (GlobeNewswire).
Otsuka Pharmaceutical’s sibeprenlimab achieved a 51.2% reduction in proteinuria versus atacicept’s 46%, raising concerns over Vera’s ability to differentiate its product, which caused Vera shares to tumble 27.9% after Otsuka’s announcement (Barron’s).
The ORIGIN 3 trial has not yet reported eGFR outcomes, and key kidney function data won’t be available until 2027, casting doubt on whether the observed proteinuria reductions will lead to the long-term renal protection needed for full FDA approval (GlobeNewswire).
Vera’s operating cash burn has increased, with net cash used in operating activities reaching $54.4 million in Q1 2025, up 61% year-over-year, bringing into question the sufficiency of its cash reserves if high spending continues (Vera Therapeutics Q1 2025 Report).
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.

VERA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VERA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VERA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs